Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 2 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Product Highlight - Forxiga

29 Mar 2019
Forxiga provides early cardiorenal benefits beyond HbA1c in a broad type 2 diabetes patient population
• Superior HbA1c reduction vs DPP4i1-2
• Well-established safety profile with no imbalance of AEs* vs placebo3-5
• Early cardiorenal benefits beyond HbA1C in a broad T2DM patients population6

*AEs included are amputations, fractures, bladder cancer or Fournier’s gangrene
Disclaimer: Forxiga is not indicated to reduce the risk of CV events, CV death or hospitalisation for heart failure or for the treatment of CKD

References:
1. Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo- controlled trial. Lancet. 2010;375(9733):2223-2233.                 
2. Rosenstock J, Mathieu C, Chen H, et al. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Arch Endocrinol Metab. 2018;62(4):424-430
3. Data on file. Atlas Approval ID: 801,453.011. AstraZeneca Pharmaceuticals Ltd.
4. FORXIGA Malaysia Prescribing Information (Doc ID-002317198, Version 13.0). April 2018
5. Jabbour S, Seufert J, Scheen A, Karup C, Langkilde AM. The incidence of amputation in the dapagliflozin clinical trial program. Endoc Pract. 2017;23(1):46A.
6. Wiviott SD, Raz I, Bonaca MP, et al. Dapaglifozin and cardiovascular outcomes in type-2 diabetes. N Engl J Med. 2018. doi: 10.1056/NEJMoa1812389

Further information is available in section 11b and in mims.com.
Full prescribing information is available upon request.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Nov 2020
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

4 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 2 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.